Lu-PSMA-Dose, a French retrospective multicentric dosimetry study of 177 Lu-PSMA treatments for metastatic castration-resistant prostate cancer | Synapse
March 3, 2026Open Access
Lu-PSMA-Dose, a French retrospective multicentric dosimetry study of 177 Lu-PSMA treatments for metastatic castration-resistant prostate cancer
Puntos clave
Metastatic castration-resistant prostate cancer treatments show potential in improving patient outcomes.
Analysis of dosimetry data for 177 Lu-PSMA indicated significant therapeutic implications for cancer treatment.
Retrospective multicentric study across various centers enhances the understanding of radiation effects.
Study indicates a need for further validation in clinical settings with larger patient samples.